What is National Diagnostics?
Founded in 1977, National Diagnostics has carved a niche as a reliable supplier of specialized chemicals. The company's diverse product lines cater to critical scientific applications, including Liquid Scintillation, Electrophoresis, and Histology, alongside offerings in Electro-Optical, and Reactive Oxygen products. This broad portfolio positions National Diagnostics as a key player supporting research and development across various scientific disciplines.
How much funding has National Diagnostics raised?
National Diagnostics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in National Diagnostics
PPP
Public-Private Partnership
What's next for National Diagnostics?
With the recent strategic investment, National Diagnostics is poised for accelerated growth and potential expansion of its product lines or market reach. The substantial total funding indicates a strong investor confidence, likely enabling the company to enhance its manufacturing capabilities, invest in further research and development, or pursue strategic partnerships. This late-stage funding suggests a focus on scaling operations and solidifying its competitive advantage in the fine chemicals market.
See full National Diagnostics company page
